LQDA241220C5000
- 0.00
- 0.000.00%
Liquidia Newsroom
Here's Arquitos Capital Management's Updates on Liquidia (LQDA)
Watching Liquidia; Hunterbrook Issues Report On Co Titled "FDA Heads to Court to Defend Unprecedented Decision Protecting Lung Drug Monopoly From Liquidia Competition"
Liquidia Insider Buyers See Boost After Market Cap Rose US$107m
Wall Street Analysts See a 126.13% Upside in Liquidia Technologies (LQDA): Can the Stock Really Move This High?
Liquidia Third Quarter 2024 Earnings: Beats Expectations
HC Wainwright & Co. Reiterates Buy on Liquidia, Maintains $29 Price Target
The Analyst Landscape: 11 Takes On Liquidia
Scotiabank Maintains Liquidia(LQDA.US) With Buy Rating, Raises Target Price to $30
A Quick Look at Today's Ratings for Liquidia(LQDA.US), With a Forecast Between $19 to $31
Liquidia Technologies (LQDA) Gets a Buy From Scotiabank
Promising Prospects of Liquidia Technologies' L606: A Game-Changer in PAH and PH-ILD Treatment
Optimistic Outlook for Liquidia Technologies: Anticipated Yutrepia Launch and Strategic Growth
Liquidia Analyst Ratings
Liquidia Corporation (LQDA) Q3 2024 Earnings Call Transcript Summary
Liquidia Corporation (LQDA) Q3 2024 Earnings Call Transcript
Liquidia Technologies: Strategic Advancements and Legal Win Bolster Buy Rating
Liquidia | 10-Q: Q3 2024 Earnings Report
Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates
Liquidia | 8-K: Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Liquidia GAAP EPS of -$0.30 Beats by $0.07, Revenue of $4.45M Beats by $0.26M